Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Atherosclerosis Reports
Published in: Current Atherosclerosis Reports 1/2011

01-02-2011 | Clinical Trial Report

Statins in Combinations: From ARBITER-6 HALTS to ACCORD—What Works?

Author: Michael Clearfield

Published in: Current Atherosclerosis Reports | Issue 1/2011

Login to get access

Excerpt

Taylor AJ, Villines TC, Stanek EJ, et al.: extended-release niacin or ezetimibe and carotid intima-thickness. N Engl J Med 2009, 361:2113–2122. …
Literature
1.
Cholesterol Treatment Trialists Collaboration. Efficacy and safety of cholesterol lowering treatment: prospective meta-analysis of data from 90056 participants in 14 randomized trials of statins. Lancet 2005;366:1267–1278.CrossRef
2.
Canner PL, Berge KG, Wenger NK et al.: Fifteen year mortality in Coronary Drug Project patients: Long term benefit with niacin. J Am Coll Cardiol 1986;8:1245–1255.CrossRefPubMed
3.
The Lipid Research Clinics coronary primary prevention trial results. Reduction in incidence of coronary heart disease. (LRC-CPPT) JAMA 1984;251:351–364.
4.
Ornish D, Brown SE, Scherwitz LW et al.: Can lifestyle changes reverse coronary heart disease? Lancet 1990;336:129–133.CrossRefPubMed
5.
Buchwald H, Varco RL, Matts JP et al.: Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report on the Program on the Surgical Control of Hyperlipidemia (POSCH) N Engl J Med 1990;323:946–955.CrossRefPubMed
6.
Ridker PM, Danielson E, Fonseca F et al.: Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359:2197–2207.CrossRef
7.
Cannon CP, Braunwald E, MCabe et al.: Intensive versus moderate lipid lowering with statins after acute coronary syndrome. N Engl J Med 2004;350:1495–1504.CrossRefPubMed
8.
Brown BG, Albers JJ, Fisher LF et al.: Regression of coronary artery disease as a result of intensive lipid lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990;323:1289–1298.CrossRefPubMed
9.
Kastelein JJ, Akdim F, Stroes E et al.: Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 2008;358:1431–1443.CrossRefPubMed
10.
Fleg JL, Mete M, Howard BV et al.: Effect of statins alone versus statins plus ezetimibe on carotid atherosclerosis in type 2 diabetes. The SANDS Trial. J Am Coll Cardiol 2008;52:2198–2205.CrossRefPubMed
11.
Brown BG, Zhao XQ, Chait A et al.: Simvastatin and niacin, antioxidant vitamins or the combination for the prevention or coronary artery disease. N Engl J Med 2001;345:1583–1592.CrossRefPubMed
12.
Bassler D, Briel M, Montori Vm et al.: STOPIT-2 Study Group. Stopping randomized trials early for benefit and estimation of treatment effects: systematic review and meta-regression analysis. JAMA 2010;303:1180–1187.CrossRefPubMed
13.
Taylor AJ, Sullenberger LE, Lee HJ et al.: Arterial Biology for the Investigation of the Treatment Effects of Reducing cholesterol (ARBITER 2). Circulation 2004;110:3512–3517.CrossRefPubMed
14.
Wilson PW, Anderson KM, Castelli WP. Twelve year incidence coronary heart disease in middle aged adults during the era of hypertensive therapy. Framingham Offspring Study. Am J Med 1991;90:11–16.CrossRefPubMed
15.
Gordon DJ, Rifkind BM. High density lipoprotein-the clinical implications of recent studies. N Engl J Med 1989;321:1311–1316.CrossRefPubMed
16.
Mosca L, Appel LJ, Benjamin EJ et al.: Evidence based guidelines for cardiovascular disease prevention in women. Circulation 2004;109:672–693.CrossRefPubMed
17.
Clearfield M. Clinical Trial Reports: Torcetrapib and the progression of coronary atherosclerosis. Curr Atheroscler Reports 2008;10:7–10.
18.
Grundy SM, Cleeman JI, Mertz CN et al.: National Heart, Lung and Blood Institute; American College of Cardiology Foundation; American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227–239.CrossRefPubMed
19.
Brown BG, Stukovsky KH, Zhao XQ. Simultaneous LDL-C lowering and HDL-C elevation for optimum cardiovascular disease prevention with various drug classes, and their combinations: a meta-analysis of 23 randomized trials. Curr Opin Lipidol 2006;17:631–636.CrossRefPubMed
20.
Duivenvoorden DS, Gorbbee DE, Kastelein JJ et al.: Ultrasound protocols to measure carotid intima –media thickness in trials; comparison of reproducibility, rate of progression and effect of intervention in subjects with familial hypercholesterolemia and subjects with mixed dyslipidemia. Ann Med 2010;
21.
Blumenthal RS, Michos ED. The HALTS Trial-Halting atherosclerosis or halted too early? N Engl J Med 2009;
22.
Zhao XQ, Krasuski RA, Baer J et al.: Effects of combination lipid therapy on coronary stenosis progression and clinical cardiovascular events in coronary disease patients with metabolic syndrome: A combined analysis of the Familial Atherosclerosis Treatment Study (FATS), the HDL-Atherosclerosis Treatment Study (HATS) and the Armed Forces Regression Study (AFREGS). Am J Cardiol 2009;104:1457–1464CrossRefPubMed
23.
Nissen SE, Nicholls SJ, Sipahi et al.: Effect of very high intensity statin therapy on regression of coronary atherosclerosis. JAMA 2006;295:1556–1565.CrossRefPubMed
24.
Nicholls SJ, Tuzcu EM, Sipahi I et al.: Statins, HDL-C and regression of coronary atherosclerosis. JAMA 2007;297:499–508.CrossRefPubMed
25.
Califf RM, Lokhnugina Y, Cannon CP et al.: An update on the IMProved reduction of outcomes: Vytorin Efficacy International Trial (IMPROVE-IT). Am Heart J 2010;159:705–709.CrossRefPubMed
Metadata
Title
Statins in Combinations: From ARBITER-6 HALTS to ACCORD—What Works?
Author
Michael Clearfield
Publication date
01-02-2011
Publisher
Current Science Inc.
Published in
Current Atherosclerosis Reports / Issue 1/2011
Print ISSN: 1523-3804
Electronic ISSN: 1534-6242
DOI
https://doi.org/10.1007/s11883-010-0142-3

Other articles of this Issue 1/2011

Current Atherosclerosis Reports 1/2011 Go to the issue

ReviewPaper

Approach to Dyslipidemia, Lipodystrophy, and Cardiovascular Risk in Patients with HIV Infection

ReviewPaper

The Anti-Ischemic and Anti-Anginal Properties of Statins

ReviewPaper

What Combination Therapy with a Statin, If Any, Would You Recommend?

ReviewPaper

Recombinant High-Density Lipoprotein Formulations

ReviewPaper

Lipid Effects of Endocrine Medications

Clinical Trial Report

A Potential Novel Therapeutic Addition to Statin Therapy for Dyslipidemia
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits